Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.
Novo Nordisk announced the submission of a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA)
Novo Holdings announced the launch of an impact fund with a total budget of $165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
Novo Nordisk today announced the headline results from the first phase 3a trial with oral semaglutide. First ever diabetes pill can change whole diabetes market replacing injection for blood sugar control.